Chinese Companies Lead the Way: Universal Artificial Platelets Tackle Global Blood Shortage and Unlock a Trillion-Dollar Market
Renerval Therapeutics
Cell Therapy Technology Developer
HemaCell
Cell Therapy Drug Developer
September 11, 2025
eMedClub News
Studies show that iPLT, derived from healthy donors and cultured under standardized conditions, can be manufactured into "off-the-shelf" products for rapid availability to different patients. Unlike traditional platelets, iPLT has a longer shelf life.Breakthrough in 5-Day Short-Term Limit，And can avoid the matching problem of rare blood types, enabling immediate infusion in clinical emergency scenarios.
This breakthrough not only marks a further advancement in China's field of stem cell and regenerative medicine clinical translation but also provides a new direction for addressing the shortage of platelet supply.
"Universal Platelets"
Cracking the Global Blood Supply Dilemma
In recent years, "blood shortage" has evolved into a常态化 crisis for global healthcare systems. Traditional platelets rely on volunteer donations and have a short shelf life.(Only 5 Days), easily contaminated and requiring strict matching,Global Annual Shortage Exceeds Ten Million Units。
In China, for example, data from the Beijing Blood Center shows that the platelet inventory gap reached over 30% in the summer of 2024.
For special groups such as patients with rare blood types and individuals with bone marrow suppression after chemotherapy, a shortage of platelets often directly endangers their lives.The dual pressures of accelerating population aging and the shrinking pool of eligible blood donors have led to a continuous intensification of the supply-demand imbalance for clinical platelets.。
The development of artificial platelet technology provides a solution to this global challenge. Taking the allogeneic iPS cell-regenerated platelets pioneered by a Chinese team as an example, HLA antigens are eliminated through gene editing.Achieving "One Type for Ten Thousand People," infusion without matching, and storage period extended to 21 days, effectively breaking through the traditional 5-day platelet storage limitation.
Currently, although the development of artificial platelets is still in the early stages, it has already shown a trend of multiple technological pathways being pursued simultaneously. These can mainly be divided into two categories:Biological and Material Types。
Biological artificial platelets, with stem cell directed differentiation at their core, can highly simulate the function of natural platelets and are suitable for long-term infusion; material-based artificial platelets, based on micro-nano particles and supramolecular materials, focus on rapid hemostasis and trauma emergency applications.
Two Enterprises in China
Leading the Development of Artificial Platelets
Currently, multiple companies worldwide have already laid out research and development of artificial platelet products. Although China started relatively late, it has made significant progress, with emerging companies such asRenerval Therapeutics, HemaCellRepresentative companies such as.
Renerval TherapeuticsChina's First Achievement in Industrial-Scale Preparation of Clinical-Grade iPSC-Derived Nucleus-Free Blood CellsThe company.
Relying on the iPSC directed differentiation technology platform, Renerval Therapeutics has achieved several core technological breakthroughs, including overcoming the bottleneck of iPSC directed differentiation efficiency and maintaining the functional homeostasis of anucleate cells.
In March 2025, Renerval Therapeutics successfully completed the world's first clinical transfusion of universal allogeneic artificial regenerated platelets.(IIT Human Clinical Trial, Product Name RBT101). This milestone marks China's leap from "0" to "1" in the field of artificial blood.
The disclosed clinical data showed that in terms of efficacy, the platelet count in patients rebounded after the infusion of RBT101 artificial platelets, and the efficacy curve showed a plateau phase without significant decline; in terms of safety, no DLT events or serious adverse events occurred.
As of now,The First Three Patients Treated Showed Good Safety DataRenerval Therapeutics stated that they will continue to increase the dose and expand the clinical sample size to further verify the effectiveness.
HemaCell is a company focused on the in vitro regeneration of hematopoietic lineages.(including blood cells and immune cells)A new type of cell therapy enterprise, itsFounder Dr. Fangfang Zhu studied under Professor Irving Weissman, known as the "Father of Stem Cells," and Professor Hongkui Deng of the School of Life Sciences at Peking University.。
The official press release pointed out that the company possesses a unique technical pathway capable of achieving a differentiation process without any gene editing, thereby obtaining platelets with high safety, high maturity, and no tumorigenic risk, which can be used for platelet transfusions in almost all age groups.
In April 2025, HemaCell's independently developedThe World's FirstPlatelet Injection XJ-PLT-001 Derived from Hematopoietic Stem CellsGranted Orphan Drug Designation by the U.S. FDA（ODD）Qualification, for massive blood lossPlatelet Syndrome and other rare diseases. This is alsoThe world's first platelet injection product to receive FDA ODD designation.
In July of the same year, XJ-PLT-001 was once again granted a second ODD qualification by the FDA for congenital amegakaryocytic thrombocytopenia.
At the same time, the company is also developing the world's first megakaryocyte injection for platelet recovery, which is also derived from hematopoietic stem cells. By covering different needs of blood users with various product categories, HemaCell is gradually building a comprehensive and multi-level blood treatment product system.
Broad Application Prospects
More Than Just Hemostasis and Emergency Care
The application value of artificial platelets goes far beyond addressing the shortage of clinical blood transfusions. With the continuous advancement of technology, their use is extending to multiple medical and non-medical fields, coveringEmergency Blood Transfusion, Disease Support, Drug Delivery, Biomanufacturing and Anti-Aging Medical CosmetologyDirections such as...
Medical Applications:
From Emergency Infusion to Disease Treatment
In medical scenarios, the most direct application of artificial platelets isAddressing the Shortage of Traditional Blood SourcesIts "no need for cross-matching, ready-to-use" feature gives it an irreplaceable advantage in emergency blood transfusion scenarios.
Developed by the Dou Hongjing team at Shanghai Jiao Tong UniversitySupramolecular Material Artificial PlateletsAchieved further technological breakthroughs: With the help of a unique structural design,Coagulation time shortened from minutes to seconds, which forms a hemostatic membrane with cells and proteins that has a tension similar to human tissue, effectively avoiding the risk of secondary bleeding. This material can also be made into various forms such as powder, sponge, or band-aid, greatly enhancing the convenience of application in emergency scenarios.
InSupportive Care for Hematological DiseasesIn terms of application potential, artificial platelets have also shown promising prospects. For instance, patients with bone marrow suppression after chemotherapy often face bleeding risks due to a sharp decline in platelet count. Traditional platelet transfusions require repeated cross-matching and their timeliness is difficult to guarantee. In contrast, "ready-to-use" artificial platelets can achieve immediate and multiple standardized infusions, significantly reducing the risks of infection and immune rejection.
In addition, artificial platelet technology also helps toPromote the Upgrade of Blood Products IndustryTraditional platelet preparations are limited by donor variability and storage conditions, leading to significant quality fluctuations, whereas standardized mass-produced artificial platelets can achieve consistency between batches, providing safer and more controllable blood substitute products for clinical use.
In the future, this technology mayFurther expansion to the in vitro regeneration of other cell types such as granulocytes and erythrocytes, fundamentally reconstructing the global blood supply system.
Non-medical applications:
Cross-Boundary Technology Integration Gives Rise to a New Ecosystem
Beyond the medical field, artificial platelets also show potential application prospects in pharmaceutical research and development, biomanufacturing, scientific research, and consumer health.
InCell CultureIn China, artificial platelets can replace traditional platelet lysate,Effectively address the issues of large batch variations and virus contamination risks. In the cultivation of stem cells and immune cells, artificial platelets can stably provide PDGF free from pathogenic contamination.(Platelet-Derived Growth Factor), TGF-β, VEGF and other key growth factors, maintain cell stemness and promote proliferation while reducing reliance on exogenous serum.(such as fetal bovine serum)Dependence.
InTissue Engineering and Regenerative MedicineIn China, artificial platelets can be used in organoid construction, wound repair material development, and other directions. Their stable bioactive components and controllable release properties help accelerate angiogenesis and tissue regeneration, providing a more controllable and safer raw material solution for biopharmaceuticals.
Drug DeliveryIs another important direction. Nanoparticles based on platelet membrane biomimicry, with their natural targeting and adhesion properties, can serve as ideal drug carriers for precise delivery of chemotherapy drugs to tumor sites or for loading growth factors to promote tissue regeneration.
In addition, inAnti-Aging and Medical Aesthetics Field, Artificial platelets are also highly promising. Platelet-rich plasma（PRP）The therapy has been widely used in skin regeneration, hair restoration, and joint injections, but its efficacy is significantly affected by individual differences in platelet quality. Standardized artificial platelets can provide "enhanced PRP" with well-defined components and stable activity, improving the consistency of treatment outcomes. For instance, a Japanese team successfully induced the differentiation of adipose-derived MSCs into platelets, which expressed markers such as CD41 and CD61 and released growth factors similar to those in PRP. The relevant findings have been published.《Scientific Reports》Publish.
Even inResearch and Industrial Scenarios, artificial platelets also provide new tools for disease modeling and high-throughput drug screening. For example, using iPSC from patients with rare platelet disorders to construct disease models can be applied in pathogenic mechanism research and drug screening evaluation, accelerating the new drug development process.
It can be said that although artificial platelets originated from clinical transfusion needs, their technological extensions are continuously expanding into multidisciplinary cross-fields such as biomanufacturing, materials science, and regenerative medicine.
Conclusion
Overall, although China has achieved the world's first clinical breakthrough in artificial platelets, this technology is still in its early stages of development and faces challenges such as improving production efficiency, cost control, and long-term safety verification.
In the future, with the deep integration of gene editing, iPSC technology, etc., artificial platelets are expected to be endowed with more functions, further expanding their therapeutic and application potential, and ultimately becoming an important foundational resource supporting clinical medicine, biomanufacturing, and regenerative innovation.
Editor-in-Chief | Xuan Xiao
Proofread by | Xuan Xiao
References:
1. Official Website and Official WeChat of the Company
2. Public Information
Exciting Live Broadcast Preview
Press and hold to scan the QR code and participate immediately ↓
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
DianDian "Share”、“Like" and "In Progress"，Give me a little recharge~"